Securities code: 603567 securities abbreviation: Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Announcement No.: pro 2022-009 Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
Announcement on the resolutions of the 14th meeting of the 4th board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
The 14th meeting of the 4th board of supervisors of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) (hereinafter referred to as “the company”) was held in the company’s conference room on January 29, 2022. Three supervisors should be present at the meeting, and there were actually three. The convening and convening procedures of the meeting shall comply with the relevant provisions of the company law of the people’s Republic of China and the Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) articles of association. The meeting was presided over by Mr. LAN Peibao, chairman of the board of supervisors of the company. After careful discussion, the attending supervisors deliberated and adopted the following matters by voting:
1、 Deliberated and passed the proposal on and its summary
The board of supervisors believes that the contents of the proposal comply with the provisions of the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of equity incentive of listed companies and other relevant laws, regulations and normative documents. The implementation of this incentive plan will be conducive to the sustainable development of the company, and there will be no damage to the interests of the company and all shareholders.
There were 0 affirmative votes and 3 abstention votes.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
For details, please refer to www.sse.com on the website of Shanghai Stock Exchange on the same day com. cn. The summary announcement of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 2022 restricted stock incentive plan (Draft) and Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 2022 restricted stock incentive plan (Draft) disclosed.
2、 Deliberated and passed the proposal on the measures for the administration of the implementation and assessment of the restricted stock incentive plan in 2022
The board of supervisors believes that the proposal conforms to the relevant national regulations and the actual situation of the company, can ensure the smooth implementation of the company’s restricted stock incentive plan in 2022, will further improve the corporate governance structure, form a good and balanced value distribution system, and establish a benefit sharing and restraint mechanism between shareholders, company managers and core backbone personnel.
There were 0 affirmative votes and 3 abstention votes.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
For details, please refer to www.sse.com on the website of Shanghai Stock Exchange on the same day com. cn. The administrative measures for the implementation and assessment of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 2022 restricted stock incentive plan disclosed.
3、 Deliberated and passed the proposal on verifying the list of incentive objects of the restricted stock incentive plan in 2022
After carefully checking the list of incentive objects, the board of supervisors believes that: the personnel listed in the list of incentive objects of the company’s restricted stock incentive plan have the qualifications specified in the company law of the people’s Republic of China, the articles of association and other laws, regulations and normative documents, and there is no situation that they have been identified as inappropriate candidates by Shanghai Stock Exchange in the last 12 months; There is no situation in which the CSRC and its dispatched offices have identified them as inappropriate candidates in the last 12 months; There are no cases in which the CSRC and its dispatched offices have imposed administrative penalties or taken market entry prohibition measures for major violations of laws and regulations in the last 12 months; There are no circumstances under which the company law stipulates that he shall not serve as a director or senior manager of the company; There is no case that the company is not allowed to participate in the equity incentive of listed companies as stipulated by laws and regulations. It meets the conditions of incentive objects specified in the administrative measures for equity incentive of listed companies and the scope of incentive objects specified in the Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 2022 restricted stock incentive plan (Draft) and its abstract. Its subject qualification as the incentive object of the company’s current incentive plan is legal and effective.
The company will publicize the names and positions of incentive objects within the company through the company’s website or other channels before the general meeting of shareholders, and the publicity period shall not be less than 10 days. The company will disclose the review opinions of the board of supervisors on the incentive list and the explanation of its publicity five days before the shareholders’ meeting deliberates the equity incentive plan.
There were 0 affirmative votes and 3 abstention votes.
For details, please refer to www.sse.com on the website of Shanghai Stock Exchange on the same day com. cn. Disclosed list of incentive objects of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 2022 restricted stock incentive plan.
It is hereby announced.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) board of supervisors February 7, 2022
